Loading
AUTHOR INFO
Thomas L. Jang
Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USAArticles List
Targeted Therapy in Non-Muscle Invasive Bladder Cancer-Clinical Updates
David Golombos , John Pfail , Rachel Passarelli , Saum Ghodoussipour , Thomas L. Jang , Vignesh T. Packiam
Non muscle invasive bladder cancer (NMIBC) comprises almost 75% of all bladder cancer (BC) diagnoses. Longstanding intravesical treatment options include chemotherapy or Bacillus Calmette-Guerin (BCG). However, despite these treatment options, there is a high rate of relapse for NMIBC patients, reaching up to 40-50% for patients with high risk disease. Radical cystectomy is recommended by guideline committees for patients with high risk NMIBC and for patients who fail intravesical treatment options
Arch Pharmacol Ther, 2024, Volume 6, Issue 1, p43-49 | DOI: 10.33696/Pharmacol.6.056
Co Authors
David Golombos
Rutgers Robert Wood Johnson University Hospital, Division of Urology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA
View Profile
John Pfail
Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
View Profile
Rachel Passarelli
Rutgers Robert Wood Johnson University Hospital, Division of Urology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA
View Profile
Saum Ghodoussipour
Rutgers Robert Wood Johnson Medical School, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
View Profile
Vignesh T. Packiam
Rutgers Robert Wood Johnson Medical School, Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA
View Profile